Related Experiment Videos
[Management of children with chronic rheumatism. Similarities and differences with rheumatoid polyarthritis]
1Service de Pédiatrie, Hôpital Necker-Enfants Malades, Paris.
Insights
Juvenile chronic arthritis (JCA) in children presents unique management challenges compared to adults, with varied treatment responses and potential growth complications. Differentiating JCA subtypes is crucial for effective pediatric rheumatology care.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Clinical Medicine
Background:
- Juvenile chronic arthritis (JCA) affects approximately 3,000 children under 16 in France.
- JCA encompasses diverse nosological entities, including systemic, polyarticular, and oligoarticular forms.
- Management of JCA in children differs significantly from adult rheumatoid arthritis (RA).
Purpose of the Study:
- To outline the challenges in managing juvenile chronic arthritis in children.
- To describe the different subtypes of JCA and their characteristics.
- To review current treatment approaches for JCA in pediatric patients.
Main Methods:
- Review of JCA classifications and clinical presentations.
- Analysis of treatment strategies for different JCA subtypes.
- Comparison of pediatric JCA management with adult RA protocols.
Main Results:
- JCA presents as systemic (20%), polyarticular (30%), or oligoarticular (50%) forms, each with distinct features.
- Treatments like NSAIDs (especially aspirin) and slow-acting drugs have specific indications and risks in children.
- Corticosteroids are reserved for aspirin-resistant systemic JCA; growth retardation is a constant complication.
Conclusions:
- Effective JCA management requires subtype-specific approaches distinct from adult RA.
- Careful consideration of treatment risks, such as NSAID intolerance and slow-acting drug contraindications, is essential.
- Long-term monitoring for complications like growth impairment is critical in pediatric patients with JCA.
Abstract:
In France, about 3,000 children under 16 years of age suffer from juvenile chronic arthritis (JCA), whose management presents a problem. JCA covers several nosological entities. In 20% of the cases, a systemic form affecting the articulations in an inconstant way, and starting in the very young child, is observed. In 30% of the cases, a form with a polyarticular start is observed. This group is very heterogeneous and includes in particular early seropositive rheumatoid arthritis (RA), the little girls' polyarthritis with presence of antinuclear antibodies, and the little boys' rheumatisms HLA B27. Finally, in 50% of the cases, an oligoarticular form is observed, also expressed in greatly varying ways. In all cases, the evolution is unpredictable and the management of these children is different from that of adults. It must be noted that the treatments used in adults are rarely applied to children as JCA is a pathology which is quite different from RA. Several types of treatment can be administered by general route: non-steroidal antiinflammatory drugs (NSAIDs) and mainly aspirin, since few NSAIDs have a paediatric licence in France. However, the risks of intolerance at doses reaching up to 100 mg/kg are not negligible. Some NSAIDs can be used in older children. The slow acting drugs are dangerous in the systemic form of JCA. Their indication seem to be more appropriate in the polyarticular forms. In the oligoarticular forms, slow acting drugs are rarely proposed. Corticosteroids are prescribed in aspirin-resistant systemic forms only. Besides the complications observed in adults, the growth is stopped in a constant way.(ABSTRACT TRUNCATED AT 250 WORDS)